Sequential combination of thalidomide and erythropoietin determines transfusion independence and disease control in idiopathic myelofibrosis previously insensitive to both drugs used as single agents.
Visani
G
G
Mele
A
A
Malagola
M
M
Isidori
A
A
Finelli
C
C
Piccaluga
P P
PP
D001803:Blood Transfusion; D019468:Disease Management; D004351:Drug Resistance; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D004921:Erythropoietin / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D008875:Middle Aged; D055728:Primary Myelofibrosis / Q000188:drug therapy*; D013792:Thalidomide / Q000008:administration & dosage*; D016896:Treatment Outcome
D004921:Erythropoietin; D013792:Thalidomide